The primary aim of the study is to identify radiomic features as biomarkers of metastatic progression following primary therapy.
The study aims to evaluate radiomic markers in breast tumors to evaluate metastatic risk based on radiomic features following primary therapy. The investigators aim to analyze images at various time intervals before, during and after primary treatments using two advanced imaging techniques (DCE-MRI \& DWI-MRI).
Study Type
OBSERVATIONAL
Enrollment
100
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Pathologic complete response (pCR)
Evaluating the degree of absence of residual cancer cells
Time frame: Up to 60 months
Time to distant breast cancer recurrence (months)
Evaluating the time until a recurrence event has occurred in the breast.
Time frame: Up to 60 months
Time to distant metastasis
Evaluating onset of distant metastasis
Time frame: Up to 60 months
Time to death
Evaluating time to cancer-related death
Time frame: Up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.